TY - JOUR
T1 - Influence of Demographic Factors on Clinical Outcomes in Adults with Chronic Idiopathic Constipation Treated with Plecanatide
AU - Rao, Satish S.C.
AU - Laitman, Adam P.
AU - Miner, Philip B.
N1 - Publisher Copyright:
Copyright ©2023 The Author(s). Published by Wolters Kluwer Health, Inc.
PY - 2023
Y1 - 2023
N2 - INTRODUCTION: Chronic idiopathic constipation (CIC) is a common condition that affects some patient groups more often. Demographic/clinical characteristics can differ in presentation and therapeutic response. The impact of these characteristics on plecanatide efficacy/safety was examined. METHODS: Data from 2 identically designed, randomized, phase 3 trials of adults with CIC receiving plecanatide 3 mg, 6 mg, or placebo for 12 weeks were analyzed. Subgroups were baseline age, body mass index (BMI), race/ethnicity, and sex/gender. Endpoints included durable overall complete spontaneous bowel movement (CSBM) responder rate, weekly CSBMs and spontaneous bowel movements (SBMs), and adverse events. RESULTS: Overall (n = 2639; plecanatide 3 mg [n = 877]; plecanatide 6 mg [n = 877]; placebo [n = 885]), CSBM responder rates were significantly greater with plecanatide 3 mg and 6 mg versus placebo in subgroups aged <65 years (P < 0.001), females (P < 0.001), whites (P < 0.001), and BMI <25 kg/m2 (P ≤ 0.004) and 25–30 kg/m2 (P < 0.001); as well, for 3 mg: ≥65 years (P = 0.03), non-whites (P < 0.001), and BMI ≥30 kg/m2 (P = 0.02). Improvement from baseline in weekly CSBM and SBM frequency occurred in all subgroups for both plecanatide doses versus placebo (P ≤0.02) at week 12, except aged ≥65 years for plecanatide 6 mg. The most common adverse event was diarrhea (3 mg [4.9%]; 6 mg [5.4%]; placebo [1.3%]). DISCUSSION: Pooled data from identically designed CIC trials strengthened the ability to identify meaningful subgroup comparisons regarding plecanatide efficacy and safety.
AB - INTRODUCTION: Chronic idiopathic constipation (CIC) is a common condition that affects some patient groups more often. Demographic/clinical characteristics can differ in presentation and therapeutic response. The impact of these characteristics on plecanatide efficacy/safety was examined. METHODS: Data from 2 identically designed, randomized, phase 3 trials of adults with CIC receiving plecanatide 3 mg, 6 mg, or placebo for 12 weeks were analyzed. Subgroups were baseline age, body mass index (BMI), race/ethnicity, and sex/gender. Endpoints included durable overall complete spontaneous bowel movement (CSBM) responder rate, weekly CSBMs and spontaneous bowel movements (SBMs), and adverse events. RESULTS: Overall (n = 2639; plecanatide 3 mg [n = 877]; plecanatide 6 mg [n = 877]; placebo [n = 885]), CSBM responder rates were significantly greater with plecanatide 3 mg and 6 mg versus placebo in subgroups aged <65 years (P < 0.001), females (P < 0.001), whites (P < 0.001), and BMI <25 kg/m2 (P ≤ 0.004) and 25–30 kg/m2 (P < 0.001); as well, for 3 mg: ≥65 years (P = 0.03), non-whites (P < 0.001), and BMI ≥30 kg/m2 (P = 0.02). Improvement from baseline in weekly CSBM and SBM frequency occurred in all subgroups for both plecanatide doses versus placebo (P ≤0.02) at week 12, except aged ≥65 years for plecanatide 6 mg. The most common adverse event was diarrhea (3 mg [4.9%]; 6 mg [5.4%]; placebo [1.3%]). DISCUSSION: Pooled data from identically designed CIC trials strengthened the ability to identify meaningful subgroup comparisons regarding plecanatide efficacy and safety.
KW - bowel movement
KW - constipation
KW - guanylate cyclase-C agonist
KW - plecanatide
KW - uroguanylin
UR - http://www.scopus.com/inward/record.url?scp=85160792771&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85160792771&partnerID=8YFLogxK
U2 - 10.14309/ctg.0000000000000598
DO - 10.14309/ctg.0000000000000598
M3 - Article
C2 - 37162147
AN - SCOPUS:85160792771
SN - 2155-384X
JO - Clinical and translational gastroenterology
JF - Clinical and translational gastroenterology
ER -